Clinical Trial

Statin Combined with Amlodipine Treats Primary Aldosteronism

Study acronym: STOP-PA
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-24; most recent amendment 2024-11-19.
Status change: Not Yet Recruiting → Recruiting 2024-11-19
Trial Details
NCT Number NCT06523465
Lead Sponsor Third Military Medical University
Conditions Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension
Enrollment 180 participants
Start Date 2024-09-10
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-22